HRS-9821
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 19, 2025
Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=134 | Recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | N=80 ➔ 134 | Trial completion date: Sep 2023 ➔ Sep 2025 | Trial primary completion date: Jul 2023 ➔ Jul 2025
Enrollment change • Trial completion date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
April 27, 2023
Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=80 | Recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
November 21, 2022
Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=80 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
New P1 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 3
Of
3
Go to page
1